Literature DB >> 1695609

Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo.

M Nose1, M Katoh, N Okada, M Kyogoku, H Okada.   

Abstract

A 20,000 molecular weight (MW) homologous restriction factor (HRF20), detected by 1F5 monoclonal antibody (mAb), is present on blood cell surfaces and inhibits the terminal stage of the formation of membrane attack complexes by homologous complement activation. The tissue distribution of HRF20 was studied by immunohistochemical analysis using 1F5. HRF20 was predominantly expressed on endothelial cells of systemic arteries, veins and capillaries, as well as on the surface of cultured human umbilical vein endothelial cells. HRF20 was also detected, to a lesser extent, on the Schwann sheath of peripheral nerve fibres, ependymal cells and certain epithelial cells such as acinar cells of the salivary gland, bronchial epithelium, renal tubules and squamous epithelium. The distribution pattern of HRF20 differed somewhat from that of decay-accelerating factor (DAF), which is another membrane inhibitor of homologous complement activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695609      PMCID: PMC1384184     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  The matrix cell and cytogenesis in the developing central nervous system.

Authors:  S FUJITA
Journal:  J Comp Neurol       Date:  1963-02       Impact factor: 3.215

2.  Complement-mediated lysis of liposomes produced by the reactive lysis procedure.

Authors:  P J Lachmann; E A Munn
Journal:  Immunology       Date:  1970-12       Impact factor: 7.397

3.  Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata.

Authors:  E M Hoffman
Journal:  Immunochemistry       Date:  1969-05

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

Authors:  A Nicholson-Weller; J Burge; D T Fearon; P F Weller; K F Austen
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

6.  Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines.

Authors:  J L Cole; G A Housley; T R Dykman; R P MacDermott; J P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

7.  Purification of 1F5 antigen that prevents complement attack on homologous cell membranes.

Authors:  R Harada; N Okada; T Fujita; H Okada
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

8.  A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement.

Authors:  N Okada; R Harada; T Fujita; H Okada
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

9.  Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.

Authors:  P J Lachmann; R A Thompson
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

10.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  27 in total

1.  CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.

Authors:  Imre Farkas; Lajos Baranyi; Yasushige Ishikawa; Noriko Okada; Csaba Bohata; Denes Budai; Atsuo Fukuda; Masaki Imai; Hidechika Okada
Journal:  J Physiol       Date:  2002-03-01       Impact factor: 5.182

2.  Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction.

Authors:  T Tada; H Okada; N Okada; H Tateyama; H Suzuki; Y Takahashi; T Eimoto
Journal:  Virchows Arch       Date:  1997-04       Impact factor: 4.064

3.  Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

4.  Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid.

Authors:  I A Rooney; B P Morgan
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

5.  Experimental lupus nephritis in severe combined immunodeficient (SCID) mice: remodelling of the glomerular lesions by bystander IgM antibodies.

Authors:  M R Ito; S Terasaki; E Kondo; H Shiwaku; Y Fukuoka; M Nose
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 6.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

7.  Binding of human and rat CD59 to the terminal complement complexes.

Authors:  T Lehto; B P Morgan; S Meri
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

Review 8.  Molecules involved in the crosstalk between immune- and peripheral nerve Schwann cells.

Authors:  Nevena Tzekova; André Heinen; Patrick Küry
Journal:  J Clin Immunol       Date:  2014-04-17       Impact factor: 8.317

9.  Spontaneous development of pancreatitis in the MRL/Mp strain of mice in autoimmune mechanism.

Authors:  H Kanno; M Nose; J Itoh; Y Taniguchi; M Kyogoku
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

10.  Induction of different types of glomerulonephritis by monoclonal antibodies derived from an MRL/lpr lupus mouse.

Authors:  J Itoh; M Nose; S Takahashi; M Ono; S Terasaki; E Kondoh; M Kyogoku
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.